Magnetoencephalography Market Size, Share, and Growth Forecast, 2026 - 2033

The global Magnetoencephalography market size is likely to be valued at US$375.6 million in 2026 and is estimated to reach US$553.7 million by 2033, growing at a CAGR of 5.7% during the forecast period 2026 − 2033, driven by rising neurological disease burden, broader clinical utilization, technology transition toward optically pumped magnetometers, and expansion of specialized neuroscience infrastructure.

Aging populations are increasing demand for neurological assessment, while advances in functional brain mapping are extending MEG utilization beyond established epilepsy applications. Regulatory acceptance of MEG systems for clinical neurodiagnostic workflows supports institutional investment where reimbursement and specialist capacity are available. Research infrastructure expansion is strengthening utilization across neuroscience, cognition, neurodevelopment, neurodegeneration, and brain-computer interface programs.

Driver - Growing Neurological Disease Burden and Demand for Functional Brain Mapping

Neurological disease prevalence is increasing the need for technologies capable of identifying abnormal brain activity with high temporal resolution. MEG supports non-invasive localization of neuronal activity and is established in clinical workflows for epilepsy evaluation and functional brain mapping. Growing demand for neurological assessment creates a broader base of potential applications across epilepsy, neurodegeneration, brain tumors, cognitive disorders, and neurodevelopment.

The World Health Organization (WHO) reported in October 2025 that neurological conditions affect more than 40% of the global population, representing more than 3 billion people. The scale of neurological disease increases pressure on health systems to improve diagnostic capacity and neurological care. MEG can complement MRI, EEG, PET, and other modalities by providing functional information that anatomical imaging cannot directly capture.

Advancement of OPM Technology and Flexible MEG Architectures

Technology development is reducing some operational barriers associated with conventional SQUID-based MEG. OPM sensors can be positioned closer to the scalp, improving adaptability to different head sizes and supporting movement-tolerant recordings. This architecture creates opportunities for pediatric neuroscience, naturalistic cognitive studies, brain-computer interfaces, and longer-duration recordings.

MAG4Health reports a room-temperature 4He OPM architecture with flexible helmet configurations and scalable sensor counts. The system is designed without a cryogenic cooling chamber and incorporates sensor localization capabilities. These characteristics can reduce infrastructure complexity and broaden potential deployment environments where conventional cryogenic systems create substantial installation requirements.

Restraint - High Infrastructure and Installation Requirements

Conventional MEG systems require specialized magnetic shielding, controlled operating environments, technical installation, and trained personnel. These requirements increase capital intensity and limit deployment in institutions without established neuroscience infrastructure. The need for dedicated space can delay procurement and reduce scalability across smaller hospitals.

Infrastructure requirements also influence operating margins because installation, calibration, maintenance, shielding, and specialist support form part of the overall ownership structure. Institutions may therefore prioritize high-utilization centers capable of supporting clinical studies and research programs rather than adopting systems across general diagnostic departments.

Specialized Supply Chain and Technical Workforce Constraints

MEG systems depend on specialized sensors, signal acquisition electronics, magnetic shielding components, software, and highly trained technical personnel. Limited availability of specialized components can extend procurement and installation timelines. Dependence on specialized engineering capabilities can also increase service costs.

Supply-chain complexity affects scalability because expansion requires synchronized availability of hardware, software, installation expertise, calibration capability, and clinical training. Smaller institutions can face greater barriers because fixed technical costs are distributed across a lower volume of examinations, which can pressure margins and delay capacity expansion.

Opportunity - Expansion of OPM-Based MEG Into Clinical and Pediatric Applications

An actionable growth pathway involves positioning OPM-MEG around applications where conventional fixed-head systems face practical limitations. Flexible sensor placement can support pediatric examinations, movement-sensitive neuroscience studies, neurodevelopmental research, and patient populations requiring greater recording flexibility. The approach can expand the addressable use environment beyond traditional fixed-position clinical assessments.

Recent installations demonstrate the commercial pathway. MAG4Health reports use of a 96-sensor system at Aston University for epilepsy, mild traumatic brain injury, and cognitive neuroscience research, with emphasis on pediatric applications. OPM systems can also support infant and fetal research, creating opportunities for specialized neuroscience programs.

Integration of MEG With Advanced Analytics and Multimodal Neuroscience

A second growth pathway involves combining MEG with EEG, MRI, computational neuroscience, artificial intelligence, and source-reconstruction platforms. Integration can increase the clinical and research value of MEG data by improving localization, functional mapping, connectivity analysis, and interpretation. Standardized data workflows can also reduce analytical complexity for institutions adopting MEG.

Research activity is moving toward network-level analysis, biomarkers, source modeling, and multimodal interpretation. A 2026 review identified functional connectivity, brain-network analysis, early Alzheimer disease research, and preoperative epilepsy evaluation as important areas in contemporary MEG research.

Product Type Insights

Cryogenic systems/conventional is anticipated to secure around 68% of the magnetoencephalography market share in 2026, reflecting established clinical infrastructure, validated workflows, and installed-system familiarity. Conventional systems remain relevant for high-performance clinical and research environments. Established whole-head MEG installations continue supporting epilepsy assessment, functional brain mapping, and advanced neuroscience research across specialized institutions.

OPM systems are expected to be the fastest-growing segment, propelled by room-temperature sensing, flexible sensor positioning, and reduced cryogenic infrastructure requirements. OPM-based systems enable closer sensor placement and adaptable helmet configurations, supporting pediatric studies, epilepsy research, and cognitive neuroscience. These characteristics can broaden deployment across specialized research facilities and emerging clinical applications.

Application Insights

Clinical is poised to dominate with a forecast market share of over 61% in 2026, powered by demand for epilepsy source localization, presurgical brain mapping, and functional assessment. MEG can complement MRI and EEG during neurological evaluation, particularly when precise localization of abnormal electrical activity is required. Clinical integration supports continued utilization across specialized neurological care settings.

Research is estimated to be the fastest-growing segment, fueled by expanding neuroscience programs, computational analysis, and interest in brain-network dynamics. Research applications increasingly cover cognition, neurodevelopment, neurodegeneration, consciousness, and brain-computer interfaces. Growing access to advanced analytical techniques is supporting broader utilization of MEG for functional connectivity, source localization, and experimental neuroscience investigations.

End-User Insights

Hospitals are likely to be the leading segment with a projected 48% of the magnetoencephalography market share in 2026, due to integration of MEG into epilepsy evaluation, functional brain mapping, and specialized neurological care. Clinical MEG programs support presurgical epilepsy assessment, where localization information can complement other diagnostic evidence and guide treatment planning across specialized neurological centers.

Academic and research institutes are anticipated to be the fastest-growing segment, fueled by neuroscience funding, advanced brain-network studies, and technology development. University-based adoption is expanding through new MEG installations, research programs, and specialized neuroscience facilities. This expansion supports research utilization, researcher training, technology validation, and development of emerging clinical and computational applications.

North America Magnetoencephalography Market Trends

North America is expected to lead with an estimated 38% of the magnetoencephalography market share in 2026, supported by established clinical MEG centers, advanced neuroscience research infrastructure, and strong adoption for epilepsy and functional brain mapping. Government-funded neuroscience programs and specialized hospitals support utilization. Established technical expertise also facilitates system maintenance, training, and integration across clinical and research environments.

U.S. Magnetoencephalography Market Insights

The U.S. is projected to account for 81% of the regional market share in 2026, supported by specialized epilepsy centers, academic neuroscience programs, and government-funded neurological research. Clinical institutions use MEG for seizure localization and presurgical planning. NIH-supported research continues advancing source modeling and analytical methods, strengthening utilization across clinical neuroscience, cognitive research, and neurodegenerative disease studies.

Canada Magnetoencephalography Market Insights

Canada is expected to account for 19% of the North America market share in 2026, supported by established whole-head MEG infrastructure and neuroscience research programs. Specialized facilities continue using MEG for clinical and research applications. Existing CTF-based installations create demand for technical maintenance and system support, while academic research sustains utilization across epilepsy, cognition, and functional brain studies.

Europe Magnetoencephalography Market Trends

Europe is projected to capture an estimated 22% of the magnetoencephalography market share in 2026, supported by neuroscience research funding, OPM technology development, and specialized institutional infrastructure. European technology developers are advancing room-temperature MEG platforms. Research centers are expanding applications across epilepsy, cognition, neurodevelopment, and brain-computer interfaces. Public research funding also supports specialized neuroimaging infrastructure and technology validation.

Germany Magnetoencephalography Market Insights

Germany is projected to account for 36% of the Europe regional market share in 2026, supported by established MEG infrastructure, clinical neuroscience capabilities, and strong research activity. Germany has active programs in conventional and OPM-based MEG. Growing investment in university-based neuroscience facilities and advanced neuroimaging research is strengthening adoption of next-generation MEG technologies across clinical and academic settings.

U.K. Magnetoencephalography Market Insights

The U.K. is expected to account for 29% of the Europe regional market share in 2026, supported by established MEG research centers and expanding OPM-MEG adoption. The University of Oxford installed an OPM-MEG scanner in June 2025. The system supports movement-based and naturalistic neuroscience studies. UK research programs also target epilepsy, cognition, neurodevelopment, and advanced brain-function mapping.

Asia Pacific Magnetoencephalography Market Trends

Asia Pacific is forecast to be the fastest-growing market for magnetoencephalography, with an estimated 22% market share in 2026, stimulated by expanding neuroscience infrastructure, university investment, and next-generation MEG deployment. China and Japan are strengthening adoption through institutional investments. New university installations and OPM deployments are expanding regional research capacity and creating opportunities for wider clinical applications.

China Magnetoencephalography Market Insights

China is projected to account for 29% of the North America market share in 2026, supported by expanding university neuroscience facilities and investment in advanced brain-imaging infrastructure. Compumedics reported an Orion LifeSpan MEG order from Hangzhou Normal University in March 2025. Planned deployments involving major universities can expand research capacity and support pediatric, cognitive, and functional neuroscience applications.

Japan Magnetoencephalography Market Insights

Japan is expected to account for 15% of the regional market share in 2026, supported by advanced neuroscience research and growing interest in room-temperature sensor technologies. MAG4Health installed its first system in Japan at the National Institute of Information and Communications Technology in March 2026. This deployment strengthens OPM-MEG visibility and supports future research applications across Japanese neuroscience institutions.

The global magnetoencephalography market is moderately consolidated, with established suppliers competing through installed-base strength, clinical validation, system performance, software integration, service capabilities, and technological differentiation. Key participants include MEGIN, Compumedics, CTF MEG, Ricoh, and MAG4Health. Competition is shifting as OPM-based technologies introduce alternative system architectures.

The competitive structure includes established SQUID-based platforms and emerging OPM-based systems. MEGIN maintains an established clinical and research presence, while Compumedics is expanding Orion LifeSpan deployments. MAG4Health is developing room-temperature OPM systems, creating a technology pathway focused on flexibility and reduced infrastructure requirements.

Key Industry Developments:

• In July 2026, MEGIN launched a side-by-side dual-MEG hyperscanning facility at Tsinghua University, strengthening advanced neuroscience research and hyperscanning capabilities in China.
• In March 2026, the University of Melbourne launched Australia’s first OPM-MEG facility, expanding next-generation brain imaging capabilities for neuroscience research and clinical applications.